In a large cohort of patients with chronic hepatitis C virus (HCV) infection, glecaprevir/pibrentasvir (G/P) administered for 8 or 12-16 weeks was found to be both effective and safe, a new study found. All HCV patients consecutively starting G/P between October 2017 and January 2018 within the NAVIGATORE-Lombardia Network were analyzed. Researchers found:
- 723 patients (median age 58 years, body mass index [BMI] 23.9 kg/m2; 50% male) were treated with G/P; 89% for 8 weeks.
- G/P combination demonstrated excellent sustained virological response (SVR) rates (99.2%).
- Male gender and non-HCV-3 genotype were associated with the lowest rates of SVR in patients treated for 8 weeks.
- No major safety issues were reported; mild adverse events were reported in 8.3% of patients.
D’Ambrosio R, Pasulo L, Puoti M, et al. Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C. [Published online ahead of print November 23, 2018]. J Hepatol. doi:10.1016/j.jhep.2018.11.011.
This Week's Must Reads
Androgen Deprivation Therapy & Risk of Depression, Cancer; ePub 2019 Feb 12; Deka, Rose, et al
QOL in Patients with Low-Risk PC Treated with HRT, JAMA Oncol; ePub 2019 Feb 14; Bruner, et al
Hospital Competition & Prostate Cancer Outcomes, Cancer; ePub 2019 Feb 1; Aggarwal, et al
Insurance Status & Stage of Prostate Ca Diagnosis, Cancer Epidemiol; 2019 Apr; Ramirez, Morano, et al
Agent Orange Exposure & Prostate Ca Outcomes, J Urol; ePub 2019 Jan 8; Etheridge, et al
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al